BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 32251624)

  • 1. Non-small-cell lung cancer brain metastases and PD-(L)1 immune checkpoint inhibitors.
    Barlesi F; Tomasini P
    Lancet Oncol; 2020 May; 21(5):607-608. PubMed ID: 32251624
    [No Abstract]   [Full Text] [Related]  

  • 2. Immunotherapy in NSCLC patients with brain metastases. Understanding brain tumor microenvironment and dissecting outcomes from immune checkpoint blockade in the clinic.
    Vilariño N; Bruna J; Bosch-Barrera J; Valiente M; Nadal E
    Cancer Treat Rev; 2020 Sep; 89():102067. PubMed ID: 32682248
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune Checkpoint Inhibitors in Brain Metastases: From Biology to Treatment.
    Berghoff AS; Venur VA; Preusser M; Ahluwalia MS
    Am Soc Clin Oncol Educ Book; 2016; 35():e116-22. PubMed ID: 27249713
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-PD-(L)1 immunotherapy for brain metastases in non-small cell lung cancer: Mechanisms, advances, and challenges.
    Zhou S; Xie J; Huang Z; Deng L; Wu L; Yu J; Meng X
    Cancer Lett; 2021 Apr; 502():166-179. PubMed ID: 33450361
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of immune checkpoint blockade for brain metastases.
    Harary M; Reardon DA; Iorgulescu JB
    CNS Oncol; 2019 Jun; 8(2):CNS33. PubMed ID: 30854898
    [No Abstract]   [Full Text] [Related]  

  • 6. Outcome of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with Checkpoint Inhibitors.
    Hendriks LEL; Henon C; Auclin E; Mezquita L; Ferrara R; Audigier-Valette C; Mazieres J; Lefebvre C; Rabeau A; Le Moulec S; Cousin S; Duchemann B; le Pechoux C; Botticella A; Ammari S; Gazzah A; Caramella C; Adam J; Lechapt E; Planchard D; De Ruysscher D; Dingemans AM; Besse B
    J Thorac Oncol; 2019 Jul; 14(7):1244-1254. PubMed ID: 30780002
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Separating or combining immune checkpoint inhibitors (ICIs) and radiotherapy in the treatment of NSCLC brain metastases.
    Li W; Yu H
    J Cancer Res Clin Oncol; 2020 Jan; 146(1):137-152. PubMed ID: 31813004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. There and back again: An immunotherapy tale.
    Guo Y; Krupnick AS
    J Thorac Cardiovasc Surg; 2018 Apr; 155(4):1771-1774. PubMed ID: 29409610
    [No Abstract]   [Full Text] [Related]  

  • 9. KEYNOTE-024: Unlocking a pathway to lung cancer cure?
    Rusch VW; Chaft J; Hellmann M
    J Thorac Cardiovasc Surg; 2018 Apr; 155(4):1777-1780. PubMed ID: 29395215
    [No Abstract]   [Full Text] [Related]  

  • 10. Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.
    Herzberg B; Campo MJ; Gainor JF
    Oncologist; 2017 Jan; 22(1):81-88. PubMed ID: 27534574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Progress of Immunotherapy Mechanisms and Current Evidence of PD-1/PD-L1 
Checkpoint Inhibitors for Non-small Cell Lung Cancer with Brain Metastasis].
    Sheng J; Yu X; Li H; Fan Y
    Zhongguo Fei Ai Za Zhi; 2020 Nov; 23(11):976-982. PubMed ID: 32773010
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
    Xia L; Liu Y; Wang Y
    Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety of Programmed Death-1 Pathway Inhibitors Among Patients With Non-Small-Cell Lung Cancer and Preexisting Autoimmune Disorders.
    Leonardi GC; Gainor JF; Altan M; Kravets S; Dahlberg SE; Gedmintas L; Azimi R; Rizvi H; Riess JW; Hellmann MD; Awad MM
    J Clin Oncol; 2018 Jul; 36(19):1905-1912. PubMed ID: 29746230
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination Therapy of Radiotherapy and Anti-PD-1/PD-L1 Treatment in Non-Small-cell Lung Cancer: A Mini-review.
    Takamori S; Toyokawa G; Takada K; Shoji F; Okamoto T; Maehara Y
    Clin Lung Cancer; 2018 Jan; 19(1):12-16. PubMed ID: 28739315
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The forgotten role of adjuvant immune checkpoint inhibitors in preventing melanoma brain metastasis.
    El Rassy E; Farhat F; Kattan J
    Immunotherapy; 2018 Nov; 10(15):1289-1291. PubMed ID: 30474477
    [No Abstract]   [Full Text] [Related]  

  • 16. Anti PD-1 and PDL-1 Immunotherapy in the Treatment of Advanced Non- Small Cell Lung Cancer (NSCLC): A Review on Toxicity Profile and its Management.
    Sgambato A; Casaluce F; Sacco PC; Palazzolo G; Maione P; Rossi A; Ciardiello F; Gridelli C
    Curr Drug Saf; 2016; 11(1):62-8. PubMed ID: 26412670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical benefit to programmed death-1 inhibition for non-small-cell lung cancer is associated with higher blood eosinophil levels.
    Sibille A; Henket M; Corhay JL; Louis R; Duysinx B
    Acta Oncol; 2020 Mar; 59(3):257-259. PubMed ID: 31755328
    [No Abstract]   [Full Text] [Related]  

  • 18. Clinical Outcomes in Patients With Metastatic Lung Cancer Treated With PD-1/PD-L1 Inhibitors and Thoracic Radiotherapy.
    Hwang WL; Niemierko A; Hwang KL; Hubbeling H; Schapira E; Gainor JF; Keane FK
    JAMA Oncol; 2018 Feb; 4(2):253-255. PubMed ID: 28973343
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Machine learning-based predictors for immune checkpoint inhibitor therapy of non-small-cell lung cancer.
    Wiesweg M; Mairinger F; Reis H; Goetz M; Walter RFH; Hager T; Metzenmacher M; Eberhardt WEE; McCutcheon A; Köster J; Stuschke M; Aigner C; Darwiche K; Schmid KW; Rahmann S; Schuler M
    Ann Oncol; 2019 Apr; 30(4):655-657. PubMed ID: 30753264
    [No Abstract]   [Full Text] [Related]  

  • 20. Current status of immune checkpoint inhibitors in treatment of non-small cell lung cancer.
    Lim SW; Ahn MJ
    Korean J Intern Med; 2019 Jan; 34(1):50-59. PubMed ID: 30612418
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.